Blackrock Inc vs Bristol-Myers Squibb Co — how do they compare? Blackrock Inc trades at $1,161.66 (market cap $177.92B), while Bristol-Myers Squibb Co trades at $63.91 (market cap $129.94B). The key difference: Blackrock Inc is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BLK | BMY | |
|---|---|---|
Market Cap | $177.92B | $129.94B |
Volume | 641,547 | — |
Sector | Financials | Health |
52-Week High | $1.20K | $65.89 |
52-Week Low | $922.90 | $42.60 |
Enterprise Value | $179.02B | $163.92B |
Dividend Yield | 2% | 3.96% |
Signals from Pluang's Aura AI — not financial advice
BLK trades at $1,159.09, up 2.45% today, with strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights BlackRock's involvement in a $500 billion AI financing initiative with Nvidia and other Wall Street firms, signaling strategic positioning in emerging technology investments.
Outlook remains positive with analyst consensus at Buy (78.79%) and a $1,350 price target, though overbought RSI levels and legal scrutiny over mutual fund practices present near-term risks. The company's expansion into tokenized money market products and sustained dividend payments support long-term growth, but investors should monitor margin pressures and regulatory developments.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Trailing returns across standard periods
Latest headlines on both assets
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →